Effects of the Self-Guided Web-Based Intervention vimida on Post–COVID-19 Fatigue: Randomized Controlled Trial (Preprint)

BACKGROUND Persistent fatigue is one of the most debilitating symptoms of post-COVID-19 condition (PCC), also referred to as Long COVID. However, evidence-based and scalable psychological interventions for managing this condition remain scarce. OBJECTIVE This study aimed to evaluate the efficacy of vimida, a self-guided, web-based intervention incorporating techniques from cognitive behavioral therapy, as an adjunct to treatment as usual (TAU) compared to TAU alone in alleviating fatigue among adults with PCC. METHODS We conducted a decentralized, pragmatic randomized controlled trial (RCT) in Germany. Adults (≥18 years) with confirmed PCC (ICD-10: U09.9), chronic fatigue syndrome (ICD-10: G93.3), and a Chalder Fatigue Scale (CFQ-11) score ≥16 were recruited online and randomized (1:1) to either vimida plus TAU (n=88) or TAU alone (n=88). The primary outcome was fatigue severity, measured by the CFQ-11 total score. Secondary outcomes included depressive symptoms (Patient Health Questionnaire-9; PHQ-9), somatic symptoms (Patient Health Questionnaire-15; PHQ-15), health-related quality of life (Assessment of Quality of Life-8D; AQoL-8D), psychosocial functioning (Work and Social Adjustment Scale; WSAS), and anxiety symptoms (Generalized Anxiety Disorder-7; GAD-7). All outcomes were assessed at 3 months, the primary time point of assessment, and at 6 months. Intention-to-treat (ITT) analyses used multiple imputation and baseline-adjusted analysis of covariance. RESULTS In the ITT analysis, vimida plus TAU significantly reduced CFQ-11 scores relative to TAU alone at 3 months (baseline-adjusted mean difference -2.04 points, 95% CI -4.07 to -0.01; P=.049; d=0.30) and 6 months (-2.6 points, 95% CI -4.6 to -0.6; P=.011; d=0.40). Following false discovery rate correction, somatic symptoms at 6 months represented the only statistically significant secondary outcome (PHQ-15: -1.8 points, 95% CI -2.8 to -0.7; P<.001; d=0.54). A prespecified response of a ≥5-point reduction on the CFQ-11 was achieved by 46.6% (41/88) of the intervention group versus 30.7% (27/88) of the control group (χ²₁=4.7; P=.03; odds ratio 1.97, 95% CI 1.06-3.65). All 88 participants in the intervention group registered and engaged with the platform on a mean of 32.4 days (SD 30.0). No adverse events were attributed to vimida. CONCLUSIONS vimida combined with TAU demonstrated small yet clinically meaningful reductions in PCC-related fatigue at 3 and 6 months, with an additional benefit for somatic symptoms at 6 months. As a fully remote intervention, vimida represents a scalable adjunctive treatment option for adults with PCC-related fatigue. CLINICALTRIAL ClinicalTrials.gov NCT06251518; InvidiCO; https://clinicaltrials.gov/study/NCT06251518

Authors

Publication Details

Published
2026-11-18
DOI
https://doi.org/10.2196/preprints.117198
Primary Topic
Long-Term Effects of COVID-19
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Effects of the Self-Guided Web-Based Intervention vimida on Post–COVID-19 Fatigue: Randomized Controlled Trial (Preprint)

Britta Menne, Gitta Anne Jacob, Christian Firus, Katharina Miriam Rischer et al.
Long-Term Effects of COVID-19
preprint

Effects of the Self-Guided Web-Based Intervention vimida on Post–COVID-19 Fatigue: Randomized Controlled Trial (Preprint)

Britta Menne, Gitta Anne Jacob, Christian Firus, Katharina Miriam Rischer, Johanna Schröder
preprint en

Abstract

BACKGROUND Persistent fatigue is one of the most debilitating symptoms of post-COVID-19 condition (PCC), also referred to as Long COVID. However, evidence-based and scalable psychological interventions for managing this condition remain scarce. OBJECTIVE This study aimed to evaluate the efficacy of vimida, a self-guided, web-based intervention incorporating techniques from cognitive behavioral therapy, as an adjunct to treatment as usual (TAU) compared to TAU alone in alleviating fatigue among adults with PCC. METHODS We conducted a decentralized, pragmatic randomized controlled trial (RCT) in Germany. Adults (≥18 years) with confirmed PCC (ICD-10: U09.9), chronic fatigue syndrome (ICD-10: G93.3), and a Chalder Fatigue Scale (CFQ-11) score ≥16 were recruited online and randomized (1:1) to either vimida plus TAU (n=88) or TAU alone (n=88). The primary outcome was fatigue severity, measured by the CFQ-11 total score. Secondary outcomes included depressive symptoms (Patient Health Questionnaire-9; PHQ-9), somatic symptoms (Patient Health Questionnaire-15; PHQ-15), health-related quality of life (Assessment of Quality of Life-8D; AQoL-8D), psychosocial functioning (Work and Social Adjustment Scale; WSAS), and anxiety symptoms (Generalized Anxiety Disorder-7; GAD-7). All outcomes were assessed at 3 months, the primary time point of assessment, and at 6 months. Intention-to-treat (ITT) analyses used multiple imputation and baseline-adjusted analysis of covariance. RESULTS In the ITT analysis, vimida plus TAU significantly reduced CFQ-11 scores relative to TAU alone at 3 months (baseline-adjusted mean difference -2.04 points, 95% CI -4.07 to -0.01; P=.049; d=0.30) and 6 months (-2.6 points, 95% CI -4.6 to -0.6; P=.011; d=0.40). Following false discovery rate correction, somatic symptoms at 6 months represented the only statistically significant secondary outcome (PHQ-15: -1.8 points, 95% CI -2.8 to -0.7; P<.001; d=0.54). A prespecified response of a ≥5-point reduction on the CFQ-11 was achieved by 46.6% (41/88) of the intervention group versus 30.7% (27/88) of the control group (χ²₁=4.7; P=.03; odds ratio 1.97, 95% CI 1.06-3.65). All 88 participants in the intervention group registered and engaged with the platform on a mean of 32.4 days (SD 30.0). No adverse events were attributed to vimida. CONCLUSIONS vimida combined with TAU demonstrated small yet clinically meaningful reductions in PCC-related fatigue at 3 and 6 months, with an additional benefit for somatic symptoms at 6 months. As a fully remote intervention, vimida represents a scalable adjunctive treatment option for adults with PCC-related fatigue. CLINICALTRIAL ClinicalTrials.gov NCT06251518; InvidiCO; https://clinicaltrials.gov/study/NCT06251518

Long-Term Effects of COVID-19
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon